These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27216761)

  • 1. Report of the Cent Gardes HIV Vaccines Conference. Part 1: The antibody response; Fondation Mérieux Conference Center, Veyrier-du-Lac, France, 25-27 October 2015.
    Girard MP; Le-Grand R; Picot V; Longuet C; Nabel GJ
    Vaccine; 2016 Jun; 34(31):3557-61. PubMed ID: 27216761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV. Part 2: Non-neutralizing antibodies: Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2984-7. PubMed ID: 23602538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Report of the 2014 Cent Gardes HIV Vaccine Conference - Part 1: Neutralizing Antibodies; Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October 2014.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2015 Jul; 33(31):3605-8. PubMed ID: 25769208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report of the 2014 Cent Gardes HIV Vaccine Conference-Part 2: Cell-mediated immunity, mucosal protection, and clinical trials: Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 October, 2014.
    Girard MP; Picot V; Longuet C; Nabel GJ
    Vaccine; 2015 Aug; 33(33):4051-5. PubMed ID: 26143614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Report of the Cent Gardes HIV Vaccines Conference, Part 2: The cellular immune response. Fondation Mérieux Conference Center, Veyrier-du-Lac, France, 25-27 October 2015.
    Girard MP; Le-Grand R; Picot V; Longuet C; Nabel GJ
    Vaccine; 2016 Nov; 34(46):5470-5473. PubMed ID: 27692524
    [No Abstract]   [Full Text] [Related]  

  • 7. Mucosal immunity and HIV/AIDS vaccines. Report of an International Workshop, 28-30 October 2007.
    Girard MP; Bansal GP; Pedroza-Martins L; Dodet B; Mehra V; Schito M; Mathieson B; Delfraissy JF; Bradac J
    Vaccine; 2008 Jul; 26(32):3969-77. PubMed ID: 18513838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
    Sadanand S; Suscovich TJ; Alter G
    Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem.
    Koff WC
    Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference.
    Ross AL; Bråve A; Scarlatti G; Manrique A; Buonaguro L
    Lancet Infect Dis; 2010 May; 10(5):305-16. PubMed ID: 20417413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological Correlates of Vaccine-Derived Protection Fondation Mérieux Conference Center 'Les Pensières' Veyrier-Du-Lac, France, Sept. 20-22, 2010.
    Schödel F
    Vaccine; 2011 Dec; 29(52):9575-7. PubMed ID: 22041303
    [No Abstract]   [Full Text] [Related]  

  • 14. AIDS research. Novel antibody response may explain HIV vaccine success.
    Cohen J
    Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167
    [No Abstract]   [Full Text] [Related]  

  • 15. RV144: old vs. new.
    Weiner DB
    Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions.
    Rubens M; Ramamoorthy V; Saxena A; Shehadeh N; Appunni S
    J Immunol Res; 2015; 2015():560347. PubMed ID: 26579546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV vaccine development--improving on natural immunity.
    Johnston MI; Fauci AS
    N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights from HIV-1 vaccine and passive immunization efficacy trials.
    Ahmed S; Herschhorn A
    Trends Mol Med; 2024 Oct; 30(10):908-912. PubMed ID: 38890027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.